SK Bioscience, under the leadership of Jae-Yong Ahn, has successfully relaunched its renowned influenza 바카라사이트 벳페어, 'SKY Cellflu'. After a hiatus of three years caused by the prioritization of COVID-19 바카라사이트 벳페어 production, SKY Cellflu's return could potentially upset the balance for competitors who gained ground in the influenza 바카라사이트 벳페어 market during its absence.

Announced on August 23rd, SK Bioscience has received official national distribution approval from the Ministry of Food and Drug Safety (MFDS) for its proprietary cell-cultured influenza 바카라사이트 벳페어, SKY Cellflu. The 바카라사이트 벳페어 will be dispatched from the state-of-the-art 'L House' production facility in Andong, Gyeongbuk. An initial batch of approximately 5 million doses is slated for distribution by early next year, with vaccinations set to commence the following month. These inoculations will be accessible at various hospitals and clinics.

Formerly a dominant player in the South Korean influenza 바카라사이트 벳페어 market, SKY Cellflu held an impressive 30% market share in 2020, generating a production value of $124 million (164.7 billion won), according to data from the Korea Food and Drug Administration (KFDA). However, production of SKY Cellflu was temporarily suspended the subsequent year due to SK Bioscience's involvement in COVID-19 바카라사이트 벳페어 development. This hiatus allowed GC Biopharma's 'GC Flu' to make substantial gains, achieving a production performance of $115 million (152.7 billion won) in 2021. In the same period, Boryung Biopharma's 'Boryung FluV Tetra' recorded $30.7 million (40.7 billion won) in production, while Il Yang Pharmaceutical's 'Teratect' reached $24.1 million (32 billion won).

The reintroduction of SKY Cellflu is poised to trigger significant shifts in the influenza 바카라사이트 벳페어 sales landscape for GC Biopharma, Boryung Biopharma, and Il Yang Pharmaceuticals. Notably, these competitors rely on the 'egg-based method' for 바카라사이트 벳페어 production, a contrast to SK Bioscience's SKY Cellflu, which employs the advanced 'cell-cultured method' utilizing animal cells. This methodology enhances safety and stability.

According to SK Bioscience, cell-cultured 바카라사이트 벳페어s are notably safe for individuals with egg allergies. Additionally, their production in a sterile environment eliminates the need for antibiotics or preservatives, reducing the risk of hypersensitivity reactions linked to traditional vaccination approaches.

In terms of effectiveness stability, the cell-cultured method outperforms the egg-based alternative. During virus cultivation, mutations can impact 바카라사이트 벳페어 efficacy. The cell-cultured approach utilized in SKY Cellflu results in fewer mutations, leading to a higher match rate with prevailing influenza viruses compared to egg-based methods (91% vs. 44%, as per the 2018 WHO study).

Crucially, SKY Cellflu offers heightened efficacy against influenza. Notably, a comparative analysis by the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) during 2017-2018 revealed an 11% greater effectiveness of the cell-cultured quadrivalent influenza 바카라사이트 벳페어 in preventing hospital visits compared to the egg-based variant. Moreover, the recent guidance from the UK's Joint Committee on Vaccination and Immunisation (JCVI) for the 2023-2024 influenza season recommends prioritizing the cell-cultured quadrivalent 바카라사이트 벳페어 for individuals aged 2 to 64 years.

Sang-Gyun Lee, Factory Manager of SK Bioscience's L House, expressed, "The return of SKY Cellflu signifies the pinnacle of advanced vaccine technology in South Korea. Through this reentry, we seek to expand citizens' vaccine choices and reestablish our competitive position in the global market."